SEC Form 10-Q filed by Third Harmonic Bio Inc.
$THRD
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/9/2024 | $12.00 → $20.00 | Equal-Weight → Overweight | Morgan Stanley |
| 6/18/2024 | $23.00 | Buy | Stifel |
| 6/7/2024 | $18.00 | Outperform | Raymond James |
8-K - Third Harmonic Bio, Inc. (0001923840) (Filer)
10-Q - Third Harmonic Bio, Inc. (0001923840) (Filer)
144 - Third Harmonic Bio, Inc. (0001923840) (Subject)
SAN FRANCISCO, March 28, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (NASDAQ:THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced the appointment of Geoff McDonough, M.D., to its Board of Directors. "Geoff is an outstanding addition to our board, bringing broad operational leadership and a depth of clinical and commercial experience that will benefit our work greatly as we advance our lead product candidate, THB335, into clinical trials for chronic spontaneous urticaria," said Natalie Holles, Chief Executive Officer of Third Harmonic Bio. "Beyond his expertise, Geoff is an excellent cultural fit with our organ
Chris brings extensive enterprise-level leadership experience in business development, commercial operations, and corporate strategy IND-enabling toxicology studies of THB335 nearing completion; Pre-IND interaction with the U.S. FDA now complete Program remains on track to file a U.S. IND and initiate a Phase 1 study of THB335 during the first half of 2024 SAN FRANCISCO, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (NASDAQ:THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced the appointment of Christopher Murphy as Chief Financial and Business Officer. Chris brings extensive experience in business de
Morgan Stanley upgraded Third Harmonic Bio from Equal-Weight to Overweight and set a new price target of $20.00 from $12.00 previously
Stifel initiated coverage of Third Harmonic Bio with a rating of Buy and set a new price target of $23.00
Raymond James initiated coverage of Third Harmonic Bio with a rating of Outperform and set a new price target of $18.00
Stifel analyst Alex Thompson initiates coverage on Third Harmonic Bio (NASDAQ:THRD) with a Buy rating and announces Price Target of $23.
Raymond James analyst Laura Prendergast initiates coverage on Third Harmonic Bio (NASDAQ:THRD) with a Outperform rating and announces Price Target of $18.
Third Harmonic Bio (NASDAQ:THRD) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.31) by 35.48 percent.
4 - Third Harmonic Bio, Inc. (0001923840) (Issuer)
4 - Third Harmonic Bio, Inc. (0001923840) (Issuer)
4 - Third Harmonic Bio, Inc. (0001923840) (Issuer)
SAN FRANCISCO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (NASDAQ:THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases, today announced that management will participate in the following upcoming conferences: Natalie Holles, Chief Executive Officer, will participate in a fireside chat at the Stifel 2024 Healthcare Conference on Tuesday, November 19, 2024, at 3:00 p.m. ESTChris Murphy, Chief Financial and Business Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 11:00 a.m. GMT / 6:00 a.m. E
THB335 Phase 1 SAD/MAD clinical trial on track to deliver clinical results in 1Q'25 Strong financial position with cash and cash equivalents totaling $296.1 million as of September 30, 2024 SAN FRANCISCO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (NASDAQ:THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory and gastrointestinal inflammatory diseases, today announced financial results for the third quarter September 30, 2024. "As the Phase 1 clinical trial of our development candidate THB335 continues toward an anticipated data readout in the first quarter of 2025, we are also making excellent progress i
SAN FRANCISCO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (NASDAQ:THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases, today announced that Chief Executive Officer Natalie Holles will participate in fireside chats at the following upcoming conferences: Stifel 2024 Virtual Immunology and Inflammation Summit on Wednesday, September 18, 2024, at 9:00 a.m. ETTD Cowen Virtual Chronic Urticaria Summit on Friday, September 20, 2024, at 3:00 p.m. ET A live audio webcast will be available within the Investors & Media section of the Third Harmonic Bio website. An archiv
SC 13G/A - Third Harmonic Bio, Inc. (0001923840) (Subject)
SC 13G - Third Harmonic Bio, Inc. (0001923840) (Subject)
SC 13D/A - Third Harmonic Bio, Inc. (0001923840) (Subject)